Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our  patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

Editor-in-Chief
Julio Licinio, MD, PhD, MBA, MS
Julio Licinio, MD, PhD, MBA, MS, FRANZCP, FAAHMS, is State University of New York (SUNY) Distinguished Professor in the Departments of Psychiatry, Pharmacology, Medicine, and Neuroscience & Physiology at SUNY Upstate Medical University (UMU). He was Senior Vice President for Academic and Health Affairs, and Executive Dean, College of Medicine at SUNY UMU in 2017-2019. He is also Matthew Flinders Distinguished Professor of Psychiatry at Flinders University in Adelaide, Australia. Prior to joining Upstate in 2017, he was Deputy Director for Translational Research and Head, Mind-Brain Theme at the South Australian Health and Medical Research Institute, and previously he was Director of the John Curtin School of Medical Research, Australian National University. Dr. Licinio was Chair of Psychiatry at University of Miami (2006-2009) and prior to that, he was at UCLA (1999-2006), where he was Center Director and Vice-Chair of Psychiatry. Dr. Licinio had clinical and research training in endocrinology and psychiatry at University of Chicago and Cornell. He is recognized internationally as a leader in translational research in depression and obesity. He has had academic apointments for over 25 years at Yale, NIH, UCLA, University of Miami, SUNY, and in Australia, where he has had key leadership positions. He is also founding Editor of three Springer Nature journals, Molecular Psychiatry, Translational Psychiatry, and The Pharmacogenomics Journal. He has most recently served as a member of the New York State Governor’s Suicide Prevention Task Force, representing SUNY.